Only Two Ring Oxygens In The Hetero Ring Which Is Not A Polycyclo Ring System (e.g., Dioxolane, Etc.) Patents (Class 514/467)
  • Patent number: 10549993
    Abstract: The present invention is directed to a method for generating oxygen comprising providing at least one oxygen source, providing at least one ionic liquid, providing at least one metal oxide compound, wherein the oxygen source is a peroxide compound, the ionic liquid is in the liquid state at least in the temperature range from ?10° C. to +50° C., and the metal oxide compound is an oxide of one single metal or of two or more different metals, said metal(s) being selected from the metals of groups 2 to 14 of the periodic table of the elements, and contacting the oxygen source, the ionic liquid, and the metal oxide compound.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: February 4, 2020
    Assignee: Diehl Aviation Gilching GmbH
    Inventors: Fritz Kuehn, Florian J. Groche, Christoph Kallfass
  • Patent number: 10214505
    Abstract: The invention describes methods of preparation and compositions of plasticizers. The ketal diester products described are useful as components of polymer compositions. The products are excellent plasticizers for a variety of polymers, such as poly(vinylchloride) plastisols.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 26, 2019
    Assignee: GFBIOCHEMICALS LIMITED
    Inventors: Brian D. Mullen, Dorie J. Yontz, Erich J. Molitor
  • Patent number: 9701656
    Abstract: Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, Wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, Parkinson's disease, and Huntington's disease.
    Type: Grant
    Filed: November 7, 2015
    Date of Patent: July 11, 2017
    Inventor: Mark Quang Nguyen
  • Patent number: 9630917
    Abstract: Cysteamine prodrugs, pharmaceutical compositions comprising the cysteamine prodrugs, and methods of using cysteamine prodrugs and pharmaceutical compositions thereof for treating eye, kidney, liver, metabolic, and neurological disorders such as cystinosis, cystinuria, non-alcoholic steatohepatitis, Batten disease, Leigh syndrome, and Huntington's disease.
    Type: Grant
    Filed: September 19, 2015
    Date of Patent: April 25, 2017
    Inventor: Mark Quang Nguyen
  • Patent number: 9562032
    Abstract: A salt which has a group represented by formula (a): wherein Xa and Xb each independently represent an oxygen atom or a sulfur group; X1 represents a C1-C12 divalent saturated hydrocarbon group which has a hydroxy group; and * represents a binding site.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: February 7, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Tatsuro Masuyama, Koji Ichikawa, Masafumi Yoshida
  • Patent number: 9206275
    Abstract: The present disclosure relates to the preparation of acrylate, alkacrylate, allyl, and polycarbonate derivatives of hydroxy ketal esters, and uses thereof.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: December 8, 2015
    Assignee: SEGETIS, INC.
    Inventors: Sergey Selifonov, Brian Daniel Mullen, Douglas Alan Wicks, Vivek Badarinarayana
  • Patent number: 9187598
    Abstract: Disclosed herein is a polyhydroxy ketal adduct obtained by the esterification of a hydrocarbon polyol by at least 1.5 equivalents of a ketocarboxy to produce an intermediate ketocarboxylic ester. The intermediate polyketocarboxylic ester is then ketalized to produce the polyhydroxyketal adduct, which can be used to provide a polymeric composition.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: November 17, 2015
    Assignee: SEGETIS, INC.
    Inventors: Brian D. Mullen, Marc D. Scholten, Dorie J. Yontz, Cora M. Leibig, Matthew J. Tjosaas
  • Publication number: 20150080386
    Abstract: Disclosed are compounds and pharmaceutical compositions that are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.
    Type: Application
    Filed: July 21, 2014
    Publication date: March 19, 2015
    Inventors: Keizo Koya, Teresa Kowalczyk Przewloka, Shoujun Chen, Jun Jiang
  • Publication number: 20150072963
    Abstract: The invention relates to compositions and methods for regulating hair growth. Specifically, the invention relates to regulating hair growth by regulating the activity one of the prostaglandin D2 (PGD2) receptors, DP-2 (GPR44). Compositions and methods for regulating hair growth include inhibiting hair growth by administering a DP-2 agonist, or stimulating hair growth by administering a DP-2 antagonist.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 12, 2015
    Inventors: George Cotsarelis, Garret Fitzgerald, Luis Garza
  • Publication number: 20150064124
    Abstract: Personal care formulations containing alkyl ketal esters having the structure wherein a is 0 or an integer of 1 to 12; b is 0 or 1; R2 is a divalent C1-8 group optionally substituted with up to 5 hydroxyl groups; and R1 is C1-6 alkyl.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: SEGETIS, INC.
    Inventors: Dorie J. YONTZ, Lee Richard RIETH, Nicholas MORANTE, Irwin PALEFSKY
  • Publication number: 20150025069
    Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Inventors: Timothy Scott Daynard, Geoffrey C. Winters, David W.C. Hunt
  • Publication number: 20150018316
    Abstract: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 15, 2015
    Inventor: Barbara Brooke Jennings
  • Patent number: 8933117
    Abstract: To provide potassium salts of substituted cycloalkene derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium (2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium (2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 13, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Nobuyuki Ohkawa, Kouki Iida, Takayoshi Nagasaki
  • Publication number: 20150010469
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Applicants: British Columbia Cancer Agency Branch, University of British Columbia
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar
  • Patent number: 8906961
    Abstract: The present disclosure relates to the preparation of ketal compounds from glycerol and levulinic acid and esters, and uses thereof, in particular the manufacture of polyurethanes.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: December 9, 2014
    Assignee: Segetis, Inc.
    Inventor: Sergey Selifonov
  • Patent number: 8901169
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 2, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • Patent number: 8901165
    Abstract: Described are alkoxylated glycerol acetals according to Formulas (Ia) and (Ib) wherein R1 represents a linear or branched, saturated or unsaturated and optionally substituted hydrocarbyl residue comprising 6 to 22 carbon atoms and 0 or 1 to 3 double bonds, a benzyl or furfuryl radical, R2 is selected from hydrogen, an alkyl, alkenyl or hydroxyalkyl group having 6 to 22 carbon atoms or an acyl group having 6 to 22 carbon atoms and 0 or 1 to 3 double bonds, AO represents an ethylene oxide, a propylene oxide, a butylene oxide unit, or their mixtures, and n is an integer of about 1 to about 100.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: December 2, 2014
    Assignee: Cognis IP Management GmbH
    Inventors: Ingo Fleute-Schlachter, Sandra Mack, Peter Kempers, Ulrich Schörken, Eckhard Paetzold, Udo Kragl
  • Patent number: 8895594
    Abstract: Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: November 25, 2014
    Assignee: Rohm and Haas Company
    Inventors: John W. Ashmore, Beverly J. El A'mma, Beat Heer, Kiran Pareek
  • Publication number: 20140343138
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: February 14, 2014
    Publication date: November 20, 2014
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran
  • Publication number: 20140336194
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: NOVARTIS AG
    Inventor: Shi Yin FOO
  • Publication number: 20140303241
    Abstract: The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 9, 2014
    Applicant: AnnCare Bio-Tech Center Inc.
    Inventors: Sheng-Chu Kuo, Jai-Sing Yang, Min-Tsang Hsieh, Tian-Shung Wu, Kuo-Hsiung Lee, Huei-Wen Chen, Li-Jiau Huang, Hsin-Yi Hung, Tzong-Der Way, Ling-Chu Chang, Hui-Yi Lin, Yung-Yi Cheng, Chin-Yu Liu
  • Publication number: 20140296240
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Gary Mark COPPOLA, Yuki IWAKI, Rajeshri Ganesh KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Muneto MOGI, Robert SUN
  • Publication number: 20140274683
    Abstract: Compositions including (a) a pollinating insect repelling, controlling, or directing compound or composition and (b) a compound or composition capable of protecting seeds, plant parts, or plants against insect and/or nematode infestation are provided. The disclosure also provides for methods of repelling, controlling, or directing a pollinating insect, for example a bee, while protecting seeds, plant parts, and/or plants against insect and/or nematode infestation. Seeds, plants, and plant parts treated with compositions described herein are also provided for by the disclosure.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 18, 2014
    Applicant: Bayer CropScience LP
    Inventors: Tai-Teh WU, Dick ROGERS, Jian ZHANG, Robert CROFT, Chi Yu Roy CHEN
  • Publication number: 20140256730
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Application
    Filed: January 13, 2014
    Publication date: September 11, 2014
    Applicant: Corsair Pharma, Inc.
    Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Publication number: 20140249213
    Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 4, 2014
    Applicant: ARBOR THERAPEUTICS, LLC
    Inventors: James D. McChesney, John T. Henri, Sylesh Kumar Venkataraman, Mahesh Kumar Gundluru
  • Publication number: 20140220122
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: BHI Limited Partnership
    Inventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
  • Patent number: 8785451
    Abstract: Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 22, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Jun Jiang
  • Publication number: 20140194496
    Abstract: Methods and compositions for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are methods and compositions for treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: BIOMAS LTD.
    Inventors: Benjamin SREDNI, Michael ALBECK
  • Publication number: 20140194497
    Abstract: Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.
    Type: Application
    Filed: February 6, 2014
    Publication date: July 10, 2014
    Applicant: R-TECH Ueno, Ltd.
    Inventors: Masato IINO, Satoshi YAMAKI, Satoshi NAKANISHI, Masahiro TAJIMA, Ryuji UENO
  • Publication number: 20140147395
    Abstract: This disclosure is directed to compound of formula (1): wherein R1 is a C7-18 alkyl, R2 is hydrogen or a C1-3 alkyl, each R3, R4, R5, R6, and R7 is independently hydrogen or a C1-6 alkyl, a is 2-3, and b is 0-1, its method of preparation and uses thereof in water-borne coating compositions, cleaning compositions, fragrance, and personal care compositions.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 29, 2014
    Applicant: SEGETIS, INC.
    Inventors: Lee R. Rieth, Dorie J. Yontz
  • Patent number: 8722729
    Abstract: The present invention relates to a compound with the following general formula (I): in which: R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation; and R2 and R3 are, independently or simultaneously: a hydrogen or a C1-C3 alkyl or a phenyl; and R4: a hydrogen atom or COR1?, where R1? is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation, advantageously 1 to 6 and preferably 1 to 4.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: May 13, 2014
    Assignee: Pierre Fabre Dermo-Cosmetique
    Inventors: Stéphane Poigny, Sylvie Daunes-Marion, Nathalie Castex Rizzi, Patrick Bogdanowicz
  • Patent number: 8716180
    Abstract: The present invention provides a method of reducing mycotoxin contamination of a plant and/or harvested plant material, said method comprising treating plant propagation material with one or more fungicides, germinating or growing said plant propagation material to produce a plant, and harvesting plant material from said plant.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: May 6, 2014
    Assignee: Syngenta Crop Protection LLC
    Inventors: Edmond Sztor, Pascal Poels, Michael Oostendorp, Franz Brandl
  • Patent number: 8716334
    Abstract: Novel substituted cyclohexylidene-ethylidene-octahydro-indene compounds and compositions comprising the same are described. The compounds exhibit profound anti-proliferative effects, in comparison to other compounds known for their anti-cancer and anti-hyperproliferative ability. Methods of use of such compounds and compositions are described for treating a variety of cancers, inflammatory and other hyperproliferative diseases and disorders.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 6, 2014
    Assignee: Ben Gurion University of the Negev Research and Development Authority
    Inventors: Shimon Ben Shabat, Amnou Sintov
  • Publication number: 20140100271
    Abstract: There is provided a compound of Formula (I) and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted alkyl group, where the aryl group is substituted, (c) an alkoxy substituted alkyl group, where the alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group, or (d) an H atom, where the substituents in (a) and (b) are hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo or fluoro groups. The compounds may be used as a medicament.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 10, 2014
    Applicant: Swedish Pharma AB c/o Inkubera AB
    Inventors: Leif A. ERIKSSON, Lennart LÖFGREN
  • Publication number: 20140073611
    Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 13, 2014
    Applicant: National Taiwan University
    Inventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
  • Publication number: 20140073689
    Abstract: To provide potassium salts of substituted pyrrolidine derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium(2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium(2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 13, 2014
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Nobuyuki Ohkawa, Kouki Iida, Takayoshi Nagasaki
  • Publication number: 20140066408
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: January 14, 2013
    Publication date: March 6, 2014
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventor: REATA PHARMACEUTICALS, INC.
  • Patent number: 8663695
    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 4, 2014
    Assignee: Mylan Specialty L.P.
    Inventor: Imtiaz Chaudry
  • Patent number: 8632792
    Abstract: A cooling sensation agent composition with a prolonged cool sensation effect is provided comprising at least one compound selected from the group consisting of aceia or ketal derivatives of 3-(1-menthoxy)propan-1,2-diol represented by Formula (1), single or mixed carbonic esters ol one or two kinds ol alcohols represented by Formula (2), and carboxylic esters represented by Formula (4). A sensory stimulation agoni composition, a flavor or fragrance composition, a beverage or food product, a perfume or cosmetic product, a toiletry product, a daily utensil product or grocery, a fiber, a fiber product, a cloth or a medicine comprising the cooling sensation agent composition; a production method thereof; a cooling processing method of a fiber, fiber product or a cloth, comprising compounding the cooling sensation agent; and new compounds are also provided.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: January 21, 2014
    Assignee: Takasago International Corporation
    Inventors: Kenya Ishida, Takashi Aida, Tetsuya Yamamoto
  • Publication number: 20140018414
    Abstract: The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 16, 2014
    Inventor: Robert J. Brosnan
  • Patent number: 8614205
    Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.
    Type: Grant
    Filed: June 2, 2012
    Date of Patent: December 24, 2013
    Inventors: Richard D Wood, William Welsh
  • Publication number: 20130316906
    Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, R4, R5, Y, Q and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as herbicides and/or pesticides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as pesticides and/or for preventing unwanted plant growth.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Alfred Angermann, Stefan Lehr, Guido Bojack, Reiner Fischer, Isolde Häuser-hahn, Ines Heinemann, Elmar Gatzweiler, Christopher Hugh Rosinger, Arnd Voerste, Dieter Feucht
  • Publication number: 20130303466
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
  • Patent number: 8530465
    Abstract: The invention provides a series of novel 1,2-disubstituted amido-anthraquinone derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with therapeutically effective amount are prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: September 10, 2013
    Assignee: National Defense Medical Center
    Inventors: Hsu-Shan Huang, Chia-Chung Lee
  • Publication number: 20130203845
    Abstract: A disinfectant solution comprising: an aldehyde; a polyol; one or more acetal derivatives formed by reaction of said aldehyde with said polyol; one or more surfactants selected from the general classes anionic, cationic, or non-ionic; one or more pH buffering agents selected from the group consisting of monosodium phosphate, disodium phosphate, trisodium phosphate, sodium tetraborate, sodium bicarbonate, sodium citrate, phosphoric acid, boric acid and citric acid. The invention also relates to a process of producing the disinfectant solution, and a method of disinfecting and/or sterilizing heat sensitive medical devices comprising treating the medical devices with the disinfectant solution of the invention.
    Type: Application
    Filed: April 27, 2011
    Publication date: August 8, 2013
    Applicant: WHITELEY CORPORATION PTY LTD.
    Inventors: Gregory Stuart Whiteley, Reginald Keith Whiteley, Graeme David Probert, Trevor Owen Glasbey
  • Publication number: 20130190370
    Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.
    Type: Application
    Filed: July 27, 2011
    Publication date: July 25, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
  • Patent number: 8492433
    Abstract: The present disclosure relates to the preparation of ketal compounds from glycerol and levulinic acid and esters, and uses thereof, in particular the manufacture of polyurethanes.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: July 23, 2013
    Assignee: Segetis, Inc.
    Inventor: Sergey Selifonov
  • Publication number: 20130178521
    Abstract: To provide potassium salts of substituted pyrrolidine derivatives, which suppress the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, and crystals thereof. The present invention provides potassium(2-chloro-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide and potassium(2-bromo-4-fluorophenyl){[(2R,3R,8R)-7-(ethoxycarbonyl)-2,3-bis(hydroxymethyl)-1,4-dioxaspiro[4.5]deca-6-en-8-yl]sulfonyl}azanide, each of which suppresses the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by endotoxin, crystals thereof, and a pharmaceutical containing any of the same, and a prophylactic and/or therapeutic agent for sepsis containing any of the same.
    Type: Application
    Filed: September 22, 2011
    Publication date: July 11, 2013
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Nobuyuki Ohkawa, Kouki Iida, Takayoshi Nagasaki
  • Patent number: 8466196
    Abstract: The present invention relates to the field of perfumery. More particularly, it concerns some acetal derivatives of 3-methyl citral of formula (I) wherein the dotted lines indicate the presence of a single or double bond; R1 represents a hydrogen atom or a methyl or ethyl group, R2 represents a hydrogen atom or methyl group; and each R3, taken alone, simultaneously or independently, represents a C1-3 alkyl or alkenyl group; or said R3 groups, taken together, represent a C2-6 hydrocarbon group optionally comprising an oxygen atom. The present invention concerns the use of said compounds in the perfumery industry as well as the compositions or articles containing said compounds.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: June 18, 2013
    Assignee: Firmenich SA
    Inventor: George Lem
  • Publication number: 20130150416
    Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.
    Type: Application
    Filed: June 2, 2012
    Publication date: June 13, 2013
    Inventors: Richard D. Wood, William Welsh